Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells

Nature Medicine

Volumn 17, Issue 12, 2011, Pages 1570-1576

  Tiscornia, Gustavo ^a   Vivas, Erica Lorenzo ^a   Belmonte, Juan Carlos Izpisúa ^a,b  

^a CENTER OF REGENERATIVE MEDICINE IN BARCELONA   (Spain)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; CELL COUNT; CELL DIFFERENTIATION; CELL TYPE; DYSAUTONOMIA; EMBRYONIC STEM CELL; GENE MUTATION; GENETIC DISORDER; HUMAN; LONG QT SYNDROME; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; SPINAL MUSCULAR ATROPHY;

ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; GENETIC DISEASES, INBORN; GENOME, HUMAN; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PHENOTYPE;

EID: 84856112882     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2504     Document Type: Review

References (38)

1. Odom D.T. et al. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat. Genet. 39, 730-732 (2007). (Pubitemid 46848594)
2. Wilson J.M. Animal models of human disease for gene therapy. J. Clin. Invest. 97, 1138-1141 (1996). (Pubitemid 26085468)
3. Perel P. et al. Comparison of treatment effects between animal experiments and clinical trials: Systematic review. Br. Med. J. 334, 197 (2007).
4. Savitz S.I. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: A need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp. Neurol. 205, 20-25 (2007). (Pubitemid 46621180)
5. Gearhart J. New potential for human embryonic stem cells. Science 282, 1061-1062 (1998). (Pubitemid 28516225)
6. Thomson J.A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998). (Pubitemid 28516247)
7. Mateizel I. et al. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum. Reprod. 21, 503-511 (2006). (Pubitemid 43159929)
8. Sermon K.D. et al. Creation of a registry for human embryonic stem cells carrying an inherited defect: Joint collaboration between ESHRE and hESCreg. Hum. Reprod. 24, 1556-1560 (2009).
9. Urbach A., Schuldiner M. & Benvenisty N. Modeling for Lesch-Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells 22, 635-641 (2004). (Pubitemid 39014579)
10. Giudice A. & Trounson A. Genetic modification of human embryonic stem cells for derivation of target cells. Cell Stem Cell 2, 422-433 (2008). (Pubitemid 351598085)
11. Takahashi K. & Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006). (Pubitemid 44233629)
12. Dimos J.T. et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321, 1218-1221 (2008).
13. Ebert A.D. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277-280 (2009).
14. Lee G. et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461, 402-406 (2009).
15. Marchetto M.C. et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-539 (2010).
16. Itzhaki I. et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471, 225-229 (2011).
17. Brennand K.J. et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221-225 (2011).
18. Liu G.H. et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472, 221-225 (2011).
19. Raya A. et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460, 53-59 (2009).
20. González F., Boue S. & Izpisua Belmonte J.C. Methods for making induced pluripotent stem cells: Reprogramming a la carte. Nat. Rev. Genet. 12, 231-242 (2011).
21. Aasen T. et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26, 1276-1284 (2008).
22. Chin M.H. et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5, 111-123 (2009).
23. Polo J.M. et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28, 848-855 (2010).
24. Ohi Y. et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat. Cell Biol. 13, 541-549 (2011).
25. Bar-Nur O., Russ H.A., Efrat S. & Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 9, 17-23 (2011).
26. Kim K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467, 285-290 (2010).
27. Stadtfeld M. et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 465, 175-181 (2010).
28. Maherali N. & Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 3, 595-605 (2008).
29. Irion S., Nostro M.C., Kattman S.J. & Keller G.M. Directed differentiation of pluripotent stem cells: From developmental biology to therapeutic applications. Cold Spring Harb. Symp. Quant. Biol. 73, 101-110 (2008).
30. Murry C.E. & Keller G. Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development. Cell 132, 661-680 (2008). (Pubitemid 351260059)
31. Moretti A. et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363, 1397-1409 (2010).
32. Yazawa M. et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471, 230-234 (2011).
33. Zhang J. et al. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 8, 31-45 (2011).
34. Liu G.H. et al. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 8, 688-694 (2011).
35. Saha K. & Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 5, 584-595 (2009).
36. Zhu H., Lensch M.W., Cahan P. & Daley G.Q. Investigating monogenic and complex diseases with pluripotent stem cells. Nat. Rev. Genet. 12, 266-275 (2011).
37. Nguyen H.N. et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8, 267-280 (2011).
38. Agarwal S. et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 464, 292-296 (2010).